Immunotherapy and Immune Evasion in Prostate Cancer
Metastatic prostate cancer remains to this day a terminal disease. Prostatectomy and radiotherapy are effective for organ-confined diseases, but treatment for locally advanced and metastatic cancer remains challenging. Although advanced prostate cancers treated with androgen deprivation therapy achi...
| Main Authors: | , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
MDPI
2013
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3730318/ |
| id |
pubmed-3730318 |
|---|---|
| recordtype |
oai_dc |
| spelling |
pubmed-37303182013-08-05 Immunotherapy and Immune Evasion in Prostate Cancer Thakur, Archana Vaishampayan, Ulka Lum, Lawrence G. Review Metastatic prostate cancer remains to this day a terminal disease. Prostatectomy and radiotherapy are effective for organ-confined diseases, but treatment for locally advanced and metastatic cancer remains challenging. Although advanced prostate cancers treated with androgen deprivation therapy achieves debulking of disease, responses are transient with subsequent development of castration-resistant and metastatic disease. Since prostate cancer is typically a slowly progressing disease, use of immune-based therapies offers an advantage to target advanced tumors and to induce antitumor immunity. This review will discuss the clinical merits of various vaccines and immunotherapies in castrate resistant prostate cancer and challenges to this evolving field of immune-based therapies. MDPI 2013-05-24 /pmc/articles/PMC3730318/ /pubmed/24216992 http://dx.doi.org/10.3390/cancers5020569 Text en © 2013 by the authors; licensee MDPI, Basel, Switzerland. http://creativecommons.org/licenses/by/3.0/ This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/). |
| repository_type |
Open Access Journal |
| institution_category |
Foreign Institution |
| institution |
US National Center for Biotechnology Information |
| building |
NCBI PubMed |
| collection |
Online Access |
| language |
English |
| format |
Online |
| author |
Thakur, Archana Vaishampayan, Ulka Lum, Lawrence G. |
| spellingShingle |
Thakur, Archana Vaishampayan, Ulka Lum, Lawrence G. Immunotherapy and Immune Evasion in Prostate Cancer |
| author_facet |
Thakur, Archana Vaishampayan, Ulka Lum, Lawrence G. |
| author_sort |
Thakur, Archana |
| title |
Immunotherapy and Immune Evasion in Prostate Cancer |
| title_short |
Immunotherapy and Immune Evasion in Prostate Cancer |
| title_full |
Immunotherapy and Immune Evasion in Prostate Cancer |
| title_fullStr |
Immunotherapy and Immune Evasion in Prostate Cancer |
| title_full_unstemmed |
Immunotherapy and Immune Evasion in Prostate Cancer |
| title_sort |
immunotherapy and immune evasion in prostate cancer |
| description |
Metastatic prostate cancer remains to this day a terminal disease. Prostatectomy and radiotherapy are effective for organ-confined diseases, but treatment for locally advanced and metastatic cancer remains challenging. Although advanced prostate cancers treated with androgen deprivation therapy achieves debulking of disease, responses are transient with subsequent development of castration-resistant and metastatic disease. Since prostate cancer is typically a slowly progressing disease, use of immune-based therapies offers an advantage to target advanced tumors and to induce antitumor immunity. This review will discuss the clinical merits of various vaccines and immunotherapies in castrate resistant prostate cancer and challenges to this evolving field of immune-based therapies. |
| publisher |
MDPI |
| publishDate |
2013 |
| url |
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3730318/ |
| _version_ |
1611999762974769152 |